pharmacogenetic algorithm

Phase 3Small molecule

UUniversity of Pernambuco

pharmacogenetic algorithm is one of 7 small molecule programs targeting MPR. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MPREnrolling by invitation

MPRPhase 3

Enrolling by invitation

Competition

Competitive Landscape

11 competitors in MPR

#DrugCompanyPhaseTrials

Lioresal

Novartis

Phase 3

1 2

Glycerin

CCalm Water Therapeutics LLC

Phase 3

1 3

pharmacogenetic algorithm

UUniversity of Pernambuco

Phase 3

1 4

Fragmin

Pfizer

Preclinical

1 5

Agenerase

GGlaxo Dba Glaxosmithkline

Preclinical

3 6

ECT-001-CB

EExCellThera inc.

Phase 2

1 7

Urine Collection

CCHU de Reims

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

MPR1 trial

Protocol for Improvement of Therapy With Warfarin

Enrolling by invitation·UUniversity of Pernambuco·Phase 3·NCT06789588·700 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pharmacogenetic algorithm. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pharmacogenetic algorithm compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pharmacogenetic algorithm. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pernambuco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Pernambuco

pharmacogenetic algorithm

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

MPR1 trial

References

Drug Info

Quick Facts

Related News